- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07537413
Ceftriaxone-dosis for ikke-kritisk samfundserhvervet lungebetændelse (DC-CAP)
Pragmatisk Randomiseret Undersøgelse, der Vurderer Doseringen af Ceftriaxon for Samfundserhvervet Lungebetændelse uden for Intensiv Afdeling
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: Jonathan D Baghdadi, MD, PhD
- Telefonnummer: 410-706-0066
- E-mail: jbaghdadi@som.umaryland.edu
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland Medical Center
-
Kontakt:
- Megan Dunning, MD
- Telefonnummer: 410-328-8667
- E-mail: mdunning@ihv.umaryland.edu
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland Medical Center - Midtown Campus
-
Kontakt:
- Jonathan Baghdadi, MD, PhD
- Telefonnummer: 410-225-8000
- E-mail: jbaghdadi@som.umaryland.edu
-
Glen Burnie, Maryland, Forenede Stater, 21061
- UM Baltimore Washington Medical Center
-
Kontakt:
- Stephanie Pires, PharmD
- Telefonnummer: 410-787-4000
- E-mail: Stephanie.Pires@umm.edu
-
Towson, Maryland, Forenede Stater, 21204
- University of Maryland St. Joseph Medical Center
-
Kontakt:
- Rose Kohinke, PharmD
- Telefonnummer: 410-337-1000
- E-mail: Rose.Kohinke@umm.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Exclusion Criteria:
- Planned or present admission to an intensive care unit
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Low Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia. |
|
Aktiv komparator: Moderate Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antibiotic escalation within 5 days of randomization
Tidsramme: The outcome will be assessed 5 days after enrollment
|
Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation |
The outcome will be assessed 5 days after enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to stability
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period |
The outcome will be assessed 90 days after enrollment
|
|
Clinical deterioration within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment
|
Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter |
The outcome will be assessed 10 days after enrollment
|
|
Ceftriaxone-associated toxicity within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment
|
Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology) |
The outcome will be assessed 10 days after enrollment
|
|
Ranked composite outcome
Tidsramme: The outcome will be assessed 30 days after enrollment
|
Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality |
The outcome will be assessed 30 days after enrollment
|
|
Duration of antibiotics
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Defined as the total days of antibiotic therapy during the hospital encounter |
The outcome will be assessed 90 days after enrollment
|
|
Hospital length of stay
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Duration of hospitalization in days |
The outcome will be assessed 90 days after enrollment
|
|
All-cause readmission
Tidsramme: The outcome will be assessed 90 days from enrollment
|
Readmission for any reason within 30 days of hospital discharge |
The outcome will be assessed 90 days from enrollment
|
|
In-hospital mortality
Tidsramme: The outcome will be assessed 90 days after enrollment
|
In-hospital death or discharge to hospice |
The outcome will be assessed 90 days after enrollment
|
|
Clostridioides difficile infection
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Positive laboratory test for Clostridioides difficile within 30 days of randomization |
The outcome will be assessed 90 days after enrollment
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HP-00117776
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .